Giovanni Caforio (Christopher Goodney/Bloomberg via Getty Images)
March 26, 2021 07:33 AM EDT
People

Hun­ker­ing down on deals and racial di­ver­si­ty pledge amid pan­dem­ic, Gio­van­ni Caforio took home $20M last year at Bris­tol My­ers Squibb

Amber Tong

Bris­tol My­ers Squibb may have tak­en a back seat in the glob­al R&D fight against Covid-19, but be­hind the scenes, the pan­dem­ic still loomed large …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times